Introduction Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae pose a
huge threat to human health, especially in the context of complicated urinary tract infections …

Extended-spectrum β-lactamase-producing Escherichia coli (ESBL-Ec) is a frequent cause
of acute pyelonephritis (APN), requiring carbapenem therapy. However, alternatives to …

Background Limited data exist regarding the efficacy of piperacillin-tazobactam (TZP) for the
management of nonbacteremic pyelonephritis caused by extended-spectrum β-lactamase …

Importance Meropenem-vaborbactam is a combination carbapenem/beta-lactamase
inhibitor and a potential treatment for severe drug-resistant gram-negative infections …

Outpatient parenteral antimicrobial therapy (OPAT) programs are becoming an increasingly
popular trend in clinical practice as they offer several benefits to both patients and health …

Objectives To re-examine the use of non-carbapenems (NCBPs), specifically piperacillin/
tazobactam and cefepime, for ESBL-producing Enterobacterales (ESBL-E) urinary tract …

Background To evaluate the short-and long-term outcomes of different antimicrobial
treatment options for upper urinary tract infections (UTIs) caused by extended-spectrum beta …

Background Urosepsis caused by extended-spectrum β-lactamase (ESBL)-producing
Escherichia coli is increasing worldwide. Carbapenems are commonly recommended for the …

Background. Vaborbactam (formerly RPX7009) is a new class of beta-lactamase inhibitor
that is being developed in combination with meropenem. The combination has potent …

Background Treating complicated urinary tract infections (cUTIs) caused by ESBL-producing
Enterobacterales represents a significant clinical challenge. The present study was thus …